You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePhendimetrazine
Accession NumberDB01579
TypeSmall Molecule
GroupsApproved, Illicit
Description

Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.

Structure
Thumb
Synonyms
Phendimetrazine
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phendimetrazine Tartratecapsule, extended release105 mg/1oralEon Labs, Inc.1977-09-062016-04-23Us
Phendimetrazine Tartratecapsule, extended release105 mg/1oralbryant ranch prepack1977-09-062016-04-05Us
Phendimetrazine Tartratecapsule, extended release105 mg/1oralPd Rx Pharmaceuticals, Inc.1977-09-062016-04-05Us
Phendimetrazine Tartratecapsule, extended release105 mg/1oralPhysicians Total Care, Inc.2009-05-112016-04-05Us
Phendimetrazine Tartratecapsule, extended release105 mg/1oralA S Medication Solutions Llc1977-09-062016-04-05Us
Phendimetrazine Tartratecapsule, extended release105 mg/1oralA S Medication Solutions Llc1977-09-062016-04-05Us
Phendimetrazine Tartratecapsule, extended release105 mg/1oralAidarex Pharmaceuticals LLC1977-09-062016-04-05Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bontrilcapsule105 mg/1oralApotheca, Inc.2010-04-082016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralEpm Packaging Inc2016-01-262016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralA S Medication Solutions Llc2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralActavis, Inc.2012-11-202016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralSolco Healthcare US LLC2011-08-012016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralApotheca, Inc.2010-04-012016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralEon Labs, Inc.1997-08-192016-04-23Us
Phendimetrazine Tartratetablet35 mg/1oralLife Line Home Care Services, Inc.2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralA S Medication Solutions Llc2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralKvk Tech, Inc2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralAidarex Pharmaceuticals LLC2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralKvk Tech, Inc2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralPreferred Pharmaceuticals, Inc.1997-08-192016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralH.J. Harkins Company, Inc.2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralRebel Distributors Corp2009-06-012016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralKvk Tech, Inc2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralElite Laboratories, Inc2012-11-202016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralA S Medication Solutions Llc2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralSTAT Rx USA LLC1977-08-192016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralBlenheim Pharmacal, Inc.2011-03-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralbryant ranch prepack2009-06-012016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralA S Medication Solutions Llc2010-09-152016-04-05Us
Phendimetrazine Tartratecapsule105 mg/1oralApotheca, Inc.2010-01-102016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralC.O. Truxton, Inc.2001-07-262016-04-23Us
Phendimetrazine Tartratetablet35 mg/1oralPhysicians Total Care, Inc.2007-06-202016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralA S Medication Solutions Llc2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralC.O. Truxton, Inc.2000-04-062016-04-23Us
Phendimetrazine Tartratetablet35 mg/1oralA S Medication Solutions Llc2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralMikart, Inc.2000-06-272016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralApotheca, Inc.1999-08-132016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralC.O. Truxton, Inc.2000-03-292016-04-23Us
Phendimetrazine Tartratetablet35 mg/1oralA S Medication Solutions Llc2010-09-152016-04-05Us
Phendimetrazine Tartratetablet35 mg/1oralMikart, Inc.2000-07-052016-04-05Us
Over the Counter ProductsNot Available
International Brands
NameCompany
AdipostNot Available
MelfiatNot Available
StatobexNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Phendimetrazine tartrate
ThumbNot applicableDBSALT001250
Categories
UNIIAB2794W8KV
CAS number634-03-7
WeightAverage: 191.2695
Monoisotopic: 191.131014171
Chemical FormulaC12H17NO
InChI KeyInChIKey=MFOCDFTXLCYLKU-UHFFFAOYSA-N
InChI
InChI=1S/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3
IUPAC Name
3,4-dimethyl-2-phenylmorpholine
SMILES
CC1C(OCCN1C)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassOxazinanes
Sub ClassMorpholines
Direct ParentPhenylmorpholines
Alternative Parents
Substituents
  • Phenylmorpholine
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.
PharmacodynamicsPhendimetrazine is a phenylalkylamine sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance has been demonstrated with all drugs of this class in which these phenomena have been looked for. Drugs of this class used in obesity are commonly known as ''anorectics or anorexigenics." It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions or metabolic effects, may be involved.
Mechanism of actionPhendimetrazine may act in a similar way to amphetamines in that it activates the alpha-adrenergic system to induce an appetite suppressive and metabolic increase effect. The drug also acts as a norepinephrine-dopamine releasing agent (NDRA). It can bind to and reverse the NET.
Related Articles
AbsorptionPeak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction

SubstrateEnzymesProduct
Phendimetrazine
Not Available
PhenmetrazineDetails
Route of eliminationThe major route of elimination is via the kidneys where most of the drug and metabolites are excreted.
Half life19-24 hours
ClearanceNot Available
ToxicityAcute overdosage of phendimetrazine may manifest itself by the following signs and symptoms: unusual restlessness, confusion, belligerance, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Poisoning may result in convulsions, coma and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9969
Blood Brain Barrier+0.9846
Caco-2 permeable+0.7977
P-glycoprotein substrateSubstrate0.6041
P-glycoprotein inhibitor INon-inhibitor0.6769
P-glycoprotein inhibitor IINon-inhibitor0.9583
Renal organic cation transporterInhibitor0.643
CYP450 2C9 substrateNon-substrate0.8398
CYP450 2D6 substrateSubstrate0.6133
CYP450 3A4 substrateSubstrate0.6142
CYP450 1A2 substrateNon-inhibitor0.7819
CYP450 2C9 inhibitorNon-inhibitor0.9346
CYP450 2D6 inhibitorNon-inhibitor0.6649
CYP450 2C19 inhibitorNon-inhibitor0.6534
CYP450 3A4 inhibitorNon-inhibitor0.8458
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8231
Ames testNon AMES toxic0.8256
CarcinogenicityNon-carcinogens0.9313
BiodegradationNot ready biodegradable0.9087
Rat acute toxicity2.6514 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7016
hERG inhibition (predictor II)Non-inhibitor0.7799
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral105 mg/1
Capsule, extended releaseoral105 mg/1
Tabletoral35 mg/1
Prices
Unit descriptionCostUnit
Bontril Slow Release 105 mg 24 Hour Capsule1.67USD capsule
Bontril sr 105 mg capsule1.1USD capsule
Phendimetrazine Tartrate 105 mg 24 Hour Capsule1.07USD capsule
Bontril pdm 35 mg tablet0.83USD tablet
Bontril 105 mg capsule sa0.48USD capsule
Phendimetrazine Tartrate 35 mg tablet0.24USD tablet
Phendimetrazine 35 mg tablet0.21USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
boiling point134.5 °C at 1.20E+01 mm HgNot Available
Predicted Properties
PropertyValueSource
Water Solubility2.43 mg/mLALOGPS
logP2.01ALOGPS
logP2.17ChemAxon
logS-1.9ALOGPS
pKa (Strongest Basic)7.28ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity57.76 m3·mol-1ChemAxon
Polarizability21.99 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.7 KB)
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Phendimetrazine.
AcepromazineAcepromazine may decrease the stimulatory activities of Phendimetrazine.
AcetazolamideAcetazolamide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
AcetophenazineAcetophenazine may decrease the stimulatory activities of Phendimetrazine.
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
AmisulprideAmisulpride may decrease the stimulatory activities of Phendimetrazine.
AmitriptylineAmitriptyline may increase the stimulatory activities of Phendimetrazine.
Ammonium chlorideThe serum concentration of Phendimetrazine can be decreased when it is combined with Ammonium chloride.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Phendimetrazine.
AripiprazoleAripiprazole may decrease the stimulatory activities of Phendimetrazine.
AtomoxetineAtomoxetine may increase the hypertensive activities of Phendimetrazine.
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Phendimetrazine.
BenzquinamideBenzquinamide may decrease the stimulatory activities of Phendimetrazine.
BrompheniraminePhendimetrazine may decrease the sedative activities of Brompheniramine.
Calcium AcetateCalcium Acetate may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
Calcium carbonateCalcium carbonate may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
CarphenazineCarphenazine may decrease the stimulatory activities of Phendimetrazine.
ChlormezanoneChlormezanone may decrease the stimulatory activities of Phendimetrazine.
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Phendimetrazine.
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Phendimetrazine.
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Phendimetrazine.
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Phendimetrazine.
ClozapineClozapine may decrease the stimulatory activities of Phendimetrazine.
DiclofenamideDiclofenamide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Phendimetrazine.
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Phendimetrazine.
DoxofyllineThe risk or severity of adverse effects can be increased when Phendimetrazine is combined with Doxofylline.
DronabinolDronabinol may increase the tachycardic activities of Phendimetrazine.
DroperidolDroperidol may decrease the stimulatory activities of Phendimetrazine.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Phendimetrazine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Phendimetrazine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Phendimetrazine.
EthoxzolamideEthoxzolamide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
FencamfamineFencamfamine may decrease the stimulatory activities of Phendimetrazine.
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Phendimetrazine.
FlupentixolFlupentixol may decrease the stimulatory activities of Phendimetrazine.
FluphenazineFluphenazine may decrease the stimulatory activities of Phendimetrazine.
FluspirileneFluspirilene may decrease the stimulatory activities of Phendimetrazine.
FormoterolThe risk or severity of adverse effects can be increased when Formoterol is combined with Phendimetrazine.
HaloperidolHaloperidol may decrease the stimulatory activities of Phendimetrazine.
HexamethylenetetramineThe serum concentration of Phendimetrazine can be decreased when it is combined with Hexamethylenetetramine.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Phendimetrazine.
Ioflupane I 123Phendimetrazine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Phendimetrazine.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Phendimetrazine.
LinezolidLinezolid may increase the hypertensive activities of Phendimetrazine.
LithiumLithium may decrease the stimulatory activities of Phendimetrazine.
LoxapineLoxapine may decrease the stimulatory activities of Phendimetrazine.
Magnesium oxideMagnesium oxide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Phendimetrazine.
MesoridazineMesoridazine may decrease the stimulatory activities of Phendimetrazine.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Phendimetrazine.
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Phendimetrazine.
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Phendimetrazine.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Phendimetrazine.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Phendimetrazine.
MolindoneMolindone may decrease the stimulatory activities of Phendimetrazine.
MorphinePhendimetrazine may increase the analgesic activities of Morphine.
NaphazolineThe risk or severity of adverse effects can be increased when Naphazoline is combined with Phendimetrazine.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Phendimetrazine.
OlanzapineOlanzapine may decrease the stimulatory activities of Phendimetrazine.
OndansetronOndansetron may decrease the stimulatory activities of Phendimetrazine.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Phendimetrazine.
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Phendimetrazine.
PaliperidonePaliperidone may decrease the stimulatory activities of Phendimetrazine.
PerphenazinePerphenazine may decrease the stimulatory activities of Phendimetrazine.
PhenelzinePhenelzine may increase the hypertensive activities of Phendimetrazine.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Phendimetrazine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Phendimetrazine.
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Phendimetrazine.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Phendimetrazine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Phendimetrazine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Phendimetrazine.
PimozidePimozide may decrease the stimulatory activities of Phendimetrazine.
PiperacetazinePiperacetazine may decrease the stimulatory activities of Phendimetrazine.
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Phendimetrazine.
PromazinePromazine may decrease the stimulatory activities of Phendimetrazine.
QuetiapineQuetiapine may decrease the stimulatory activities of Phendimetrazine.
RemoxiprideRemoxipride may decrease the stimulatory activities of Phendimetrazine.
ReserpineReserpine may decrease the stimulatory activities of Phendimetrazine.
RisperidoneRisperidone may decrease the stimulatory activities of Phendimetrazine.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Phendimetrazine.
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Phendimetrazine.
SertindoleSertindole may decrease the stimulatory activities of Phendimetrazine.
SulpirideSulpiride may decrease the stimulatory activities of Phendimetrazine.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Phendimetrazine.
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Phendimetrazine.
ThioridazineThioridazine may decrease the stimulatory activities of Phendimetrazine.
ThiothixeneThiothixene may decrease the stimulatory activities of Phendimetrazine.
TranylcypromineTranylcypromine may increase the hypertensive activities of Phendimetrazine.
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Phendimetrazine.
TriflupromazineTriflupromazine may decrease the stimulatory activities of Phendimetrazine.
Vitamin CThe serum concentration of Phendimetrazine can be decreased when it is combined with Vitamin C.
ZiprasidoneZiprasidone may decrease the stimulatory activities of Phendimetrazine.
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Phendimetrazine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Bray GA: Drug Insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol. 2005 Feb;2(2):89-95. [PubMed:16265126 ]
  4. Bray GA: A concise review on the therapeutics of obesity. Nutrition. 2000 Oct;16(10):953-60. [PubMed:11054601 ]
  5. Rothman RB, Baumann MH: Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem. 2006;6(17):1845-59. [PubMed:17017961 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
negative modulator
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Rothman RB, Baumann MH: Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem. 2006;6(17):1845-59. [PubMed:17017961 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Bray GA: Drug Insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol. 2005 Feb;2(2):89-95. [PubMed:16265126 ]
  4. Bray GA: A concise review on the therapeutics of obesity. Nutrition. 2000 Oct;16(10):953-60. [PubMed:11054601 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Rothman RB, Baumann MH: Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem. 2006;6(17):1845-59. [PubMed:17017961 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 08:52 / Updated on January 29, 2014 08:32